LACK OF SYNERGY BETWEEN CISPLATIN AND CYTARABINE AGAINST OVARIAN-CARCINOMA INVITRO
- 1 March 1986
- journal article
- research article
- Vol. 70 (3) , 409-410
Abstract
Synergy has been reported for the combination of cisplatin and cytarabine in a murine model and in several human cell lines in vitro. Clinical trials are under way with this combination. However, we were unable to demonstrate any significant synergistic interaction between these two agents in two human ovarian carcinoma cell lines with either 4-hour or continuous concurrent exposure in vitro at drug concentration producing 1-2 logs of cell kill. Synergy between these two drugs may be limited to unique cell lines and tumors.This publication has 4 references indexed in Scilit:
- Intraperitoneal cytosine arabinoside therapy in ovarian carcinoma.Journal of Clinical Oncology, 1984
- Intraperitoneal Cisplatin with Systemic Thiosulfate ProtectionAnnals of Internal Medicine, 1982
- COMPARISON OF 4 NEW CELL-LINES FROM PATIENTS WITH ADENOCARCINOMA OF THE OVARY1979
- COMBINATION CHEMOTHERAPY INVITRO WITH CIS-DICHLORODIAMMINEPLATINUM(II)1976